SOD1 and amyotrophic lateral sclerosis: More recently, a phase I-II ascending-dose trial (NCT02623699) was conducted to evaluate the safety, pharmacokinetics and pharmacodynamics of tofersen in ALS cases carrying SOD1 mutation [33].